Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study
PurposeWe aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain.MethodsThis was a multicenter, observational, retr...
| Autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2026 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:dnet:r-fisabio___::76b2e50c8e32c4181413ed5002ee3c04 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/20574 |
| Access Level: | acceso abierto |
| Palabra clave: | nmCRPC mCRPC Real-world evidence Darolutamide Abiraterone Docetaxel Cabazitaxel |
| Sumario: | PurposeWe aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain.MethodsThis was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study.Results85 patients, with a median age of 76 years, were included in the study. 49 patients (57.6%) progressed to mCRPC, with metastases located mainly in bone. Only 35 of them (71.4%) received at least one subsequent therapy. The most common first-line treatments after darolutamide were abiraterone (n = 22, 63%) and docetaxel (n = 10, 29%), with a median (IQR) treatment duration of 7.6 months (4.7, 12.7) and 4.8 months (3.8, 5.8), respectively; besides, the most frequent first-line/second-line treatment sequences were abiraterone-docetaxel and docetaxel-cabazitaxel. In addition, only 20% of patients with bone metastases received osteoclast-targeted therapy.ConclusionThese real-world practice patterns suggest a lack of consensus in Spanish clinical practice for the management of patients with mCRPC, indicating that there is a need for more standardized strategies and unification of the criteria to make decisions in accordance with the recommendations of international clinical practice guidelines.Clinical trial registrationNot applicable. |
|---|